Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Growth in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) saw a large growth in short interest during the month of August. As of August 31st, there was short interest totaling 15,579 shares, a growth of 1,923.2% from the August 15th total of 770 shares. Based on an average trading volume of 17,581 shares, the short-interest ratio is presently 0.9 days. Approximately 0.9% of the shares of the stock are sold short.

Bolt Biotherapeutics Stock Up 1.4%

Shares of BOLT stock traded up $0.05 during trading on Thursday, hitting $3.73. 96,975 shares of the company were exchanged, compared to its average volume of 25,388. The business’s 50-day simple moving average is $3.87 and its 200 day simple moving average is $4.35. Bolt Biotherapeutics has a twelve month low of $3.13 and a twelve month high of $7.20. The firm has a market capitalization of $7.18 million, a price-to-earnings ratio of -0.23 and a beta of 1.09. The company has a debt-to-equity ratio of 1.47, a quick ratio of 2.61 and a current ratio of 2.61.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Tuesday, August 11th. The company reported ($4.57) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. As a group, analysts forecast that Bolt Biotherapeutics will post -11.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Bolt Biotherapeutics

A number of hedge funds have recently added to or reduced their stakes in BOLT. T3 Companies LLC bought a new position in shares of Bolt Biotherapeutics during the 4th quarter valued at $208,000. Renaissance Technologies LLC increased its position in Bolt Biotherapeutics by 92.2% during the fourth quarter. Renaissance Technologies LLC now owns 55,025 shares of the company’s stock worth $301,000 after buying an additional 26,400 shares during the last quarter. Nano Cap New Millennium Growth Fund L P bought a new position in Bolt Biotherapeutics during the fourth quarter valued at about $112,000. Susquehanna International Group LLP acquired a new stake in shares of Bolt Biotherapeutics in the third quarter worth about $89,000. Finally, Shay Capital LLC acquired a new stake in shares of Bolt Biotherapeutics in the third quarter worth about $85,000. Institutional investors and hedge funds own 86.70% of the company’s stock.

Wall Street Analysts Forecast Growth

BOLT has been the subject of several analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $7.00 target price on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Rodman & Renshaw initiated coverage on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $22.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. Two equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $14.50.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.